We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
Read MoreHide Full Article
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.36, marking a -5.56% move from the previous day. This change lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.59%, and the technology-dominated Nasdaq saw a decrease of 0.05%.
Heading into today, shares of the maker of genetic analysis technology had gained 2.86% over the past month, lagging the Medical sector's gain of 6.06% and outpacing the S&P 500's gain of 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings report is set to go public on August 5, 2026. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $40.7 million, indicating a 2.34% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.41 per share and a revenue of $165.8 million, representing changes of +22.64% and +3.62%, respectively, from the prior year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Pacific Biosciences of California boasts a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 175, putting it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
In the latest trading session, Pacific Biosciences of California (PACB - Free Report) closed at $1.36, marking a -5.56% move from the previous day. This change lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.59%, and the technology-dominated Nasdaq saw a decrease of 0.05%.
Heading into today, shares of the maker of genetic analysis technology had gained 2.86% over the past month, lagging the Medical sector's gain of 6.06% and outpacing the S&P 500's gain of 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings report is set to go public on August 5, 2026. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $40.7 million, indicating a 2.34% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.41 per share and a revenue of $165.8 million, representing changes of +22.64% and +3.62%, respectively, from the prior year.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Pacific Biosciences of California boasts a Zacks Rank of #3 (Hold).
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 175, putting it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.